Efficacy and safety of chloroquine for treatment of COVID-19. An open-label, multi-center, non-randomized trial

Zhong Nanshan (钟南山), Mar 2020

Source

PDF

All
Studies

Meta
Analysis

https://c19hcq.org/zhong2.html

HCQ for COVID-19

1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 423 studies, used in 59 countries.

Lower risk for mortality, hospitalization, progression, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,700+ studies for 141 treatments. c19hcq.org

197 patients. CQ effective. Day 10 viral RNA negative 91.4% HCQ versus 57.4% control. Median time to negative test 3 days versus 9 days for control.

Standard of Care (SOC) for COVID-19 in the study country, China, is poor with low average efficacy for approved treatments1.

Important missing comments or errors? Let us know.

risk of no virological cure at day 10, 80.0% lower, RR 0.20, p < 0.001, treatment 5 of 115 (4.3%), control 17 of 82 (20.7%), NNT 6.1, adjusted per study.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. c19early.org, c19early.org/soc/china.html.c19early.org/soc/china.html.

Zhong Nanshan (钟南山) et al., 26 Mar 2020, retrospective, China, preprint, 1 author.

This Paper HCQ All

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0